Pharmaceuticals News and Research

RSS

Derma Sciences to initiate DSC127 Phase 3 program in diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.S. Food and Drug Administration (FDA), the Company plans to begin its Phase 3 program in December 2012 in support of a New Drug Application (NDA) for DSC127 for treatment of diabetic foot ulcers.

23 Oct 2012

Pfizer announces intention to acquire NextWave

Pfizer Inc. today announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

23 Oct 2012

John Theurer Cancer Center, LRF to host Ask the Doctor About Lymphoma

The Lymphoma Research Foundation (LRF), the nation's largest non-profit organization devoted to lymphoma research, is partnering with John Theurer Cancer Center, one of the nation's 50 best hospitals for cancer, to bring the lymphoma community information about the rapidly changing world of lymphoma treatment.

23 Oct 2012

Adachi purchases Mazor Robotics' Renaissance surgical guidance system for spine procedures

Mazor Robotics Ltd., a developer of innovative surgical robots and complementary products, today announced that Adachi Medical Instruments Co., Mazor's distribution partner in Japan, placed an order for its Renaissance™ system. As part of the distribution agreement, Adachi is committed to obtain Japanese PMDA (Pharmaceuticals and Medical Devices Agency) approval for the Renaissance system.

22 Oct 2012

New data on Posiphen for Alzheimer's disease treatment to be presented at Biotech Symposium

QR Pharma, Inc., a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound "Posiphen® Recovers Memory, Learning and Brain Function in Alzheimer Transgenic Mice" at the 12th Annual Biotech Symposium, taking place October 22, 2012 in Philadelphia, PA.

22 Oct 2012

Initiation of dinaciclib Phase 2b/3 CLL trial triggers $2M milestone payment from Merck

Ligand Pharmaceuticals Incorporated today announced that it will receive a $2 million milestone payment from Merck, known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib.

22 Oct 2012

Liquid version of breast cancer drug Tamoxifen launched in the US

Breast Cancer Awareness Month raises visibility and research dollars to address a disease that in the United States claims nearly 40,000 lives annually and affects approximately 240,000 people who each year are newly diagnosed. While the month's activities are important in the fight against breast cancer, they are not designed to directly improve the day-to-day management of the disease.

22 Oct 2012

PLoS ONE publishes review of AntiViral-HyperActivation Limiting Therapeutics clinical trial

ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE.

22 Oct 2012

EvaluatePharma's Tracking Drugs@FDA provides regulatory approval analysis

EvaluatePharma, the premier source for life science sector analysis and consensus forecasts, today launched a new service enhancement, Tracking Drugs@FDA, which gives clients access to the entire universe of approved FDA drugs and the related FDA document library as well as FDA Orange Book patent data - all fully integrated into the industry-leading EvaluatePharma platform and analytical tools.

22 Oct 2012

Patients with AF experience more GI bleeding with rivaroxaban use

Patients with atrial fibrillation (AF) experienced more major and non-major clinically relevant GI bleeding when taking rivaroxaban than patients taking warfarin.

22 Oct 2012

Bayer announces data from riociguat Phase III pulmonary arterial hypertension trial

Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug riociguat in both treatment-naive patients and those pre-treated with an endothelin receptor antagonist or an oral, inhaled or subcutaneous prostanoid.

22 Oct 2012

Simple five-question survey may lead to increased diagnoses of COPD

A simple, five-question patient-administered survey (COPD-PS) may lead to increased diagnoses of chronic obstructive pulmonary disease (COPD).

22 Oct 2012

Physician shares lessons learned from fungal meningitis outbreak

In a new perspective piece being published Online First tonight in Annals of Internal Medicine, a physician recalls lessons learned from treating patients affected by the 2002 outbreak of Exophiala (Wangiella) dermatitidis meningitis or arthritis related to contaminated, injectable coticosteroids prepared from a compounding pharmacy.

20 Oct 2012

University of Kentucky to host Makenna Foundation Symposium on Pediatric Pulmonary Disease

The University of Kentucky is hosting the first annual Makenna Foundation Symposium on Pediatric Pulmonary Disease next Friday and Saturday.

20 Oct 2012

True scale of anti-psychotic usage in dementia may be under-estimated

The scale of the challenge to reduce the use of anti-psychotic drugs by people with dementia may be under-estimated, according to researchers from Aston University and the University of East Anglia, working with NHS Kent and Medway. There is a key public health challenge to reduce the prescribing of anti-psychotic drugs to people with dementia as they are thought to be associated with up to 1,800 deaths a year.

19 Oct 2012

EMA CHMP issues positive opinion to Savient's KRYSTEXXA for treatment of chronic gout

Savient Pharmaceuticals, Inc. and its wholly owned subsidiary, Savient Pharma Ireland Limited, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has completed its scientific assessment and has issued a positive opinion recommending approval of a marketing authorization in the European Union for KRYSTEXXA for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.

19 Oct 2012